Loading data for ORGO — first visit, this takes a few seconds.

알림

Organogenesis Inc. (ORGO)

NasdaqCM: ORGO · 실시간 가격 · USD

1.79

+0.07 (4.07%)

종가 기준: Aug 19, 2026, 8:00 PM

1.88

-1.57%

애프터마켓: 4:00 PM

4.07% (1D)

데이터 없음

매수호가	1.29
시가총액	245.77M
매출 (ttm)	457.45M
순이익 (ttm)	-101.68M
베타	1.32
EPS (ttm)	-0.79
P/E (ttm)	n/a
선행 P/E	-6.16
P/B (ttm)	1.66
P/S (ttm)	0.54
Earnings Date	May 10, 2022

매도호가	2.22
거래량	642,319
평균 거래량 (20일)	863,661
시가	1.73
전일 종가	1.72
일중 범위	1.73 - 1.80
52주 범위	1.54 - 7.08
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ORGO 소개

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioen...

섹터 Healthcare

IPO 일자 Jan 5, 2017

직원 수 854

상장 거래소 NasdaqCM

티커 ORGO

웹사이트 https://organogenesis.com

전체 기업 정보

재무 실적

2025년 Organogenesis의 매출은 563.03M로, 전년 482.04M 대비 16.8% 증가했습니다. 순이익은 37.03M로, 4,201.05% 증가했습니다.

재무제표

어닝 서프라이즈

Organogenesis가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $42.8M 예상치 하회 $0, 및 -57.53% 전년 대비 감소.

EPS -0.69 예상치 하회 -0.34, 및 -1050.00% 전년 대비 감소.

다음 실적 발표

Organogenesis Inc.의 실적 발표 예정일은 May 10, 2022, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Simply Wall St.

Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution

The latest update on Organogenesis Holdings centers on a cut to the assessed fair value and price target from US$3.00 to US$2.00, which marks a reduction of around one third. Analysts framing this shi...

1주 전 · Simply Wall St.

Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?

In August 2026, Organogenesis Holdings Inc. reported second-quarter revenue of US$43.76 million and a net loss of US$96.27 million, alongside sharply reduced full-year 2026 revenue guidance and a US$7...

1주 전 · Moby

Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary

Moby summary of Organogenesis Holdings Inc.'s Q2 2026 earnings call

1주 전 · MarketBeat

Organogenesis Q2 Earnings Call Highlights

Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Med...

3개월 전 · Insider Monkey

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Organogenesis Holdings Inc. (NASDAQ:ORGO) is one of the best pharmaceutical stocks on our list. TheFly reported on M...

2 페이지 중 1

Organogenesis Inc. (ORGO)